Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
BiondVax financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$3.6
2024-10-29
Market Capitalization
$3.1 M
2024-10-29
Revenue
$1.3 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 14, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| ILS | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 658.0K | 1.3M | ||||||
| Cost of goods sold | 1.2M | 4.0M | ||||||
| Gross profit | 12.7M | 40.0K | 9.0K | (580.0K) | (2.7M) | |||
| Gross profit margin, % | -88.1% | -202.3% | ||||||
| Operating expense total | 76.7M | 76.7M | 66.6M | 33.4M | 10.5M | 9.2M | 6.4M | 3.5M |
| Depreciation and amortization | 260.0K | 1.6M | 1.5M | 1.5M | 562.0K | 514.0K | 1.6M | 1.4M |
| EBITDA | (76.7M) | (76.7M) | (54.0M) | (33.3M) | (10.5M) | (9.2M) | (7.0M) | (6.1M) |
| EBITDA margin, % | -1062.3% | -467.0% | ||||||
| EBIT | (81.3M) | (78.4M) | (55.5M) | (34.8M) | (11.1M) | (9.7M) | 6.1M | (7.5M) |
| EBIT margin, % | 930.2% | -575.3% | ||||||
| Interest income | 100.0K | 4.0K | 2.0K | 3.0K | ||||
| Interest expense | 9.2M | 15.1M | 1.2M | 10.9M | 5.1M | 1.4M | 359.0K | |
| Pre tax profit | (87.5M) | (109.2M) | (4.5M) | (40.0M) | (5.8M) | (6.5M) | 4.8M | (8.3M) |
| Net Income | (87.5M) | (109.2M) | (4.5M) | (40.0M) | (5.8M) | (6.5M) | 4.8M | (8.3M) |